Stay updated on A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedVirogen Biotechnology Inc. was added as sponsor and Angimmune LLC was removed as a collaborator. The study record revision was updated from v3.5.3 to v3.5.4.SummaryDifference0.3%

- Check25 days agoNo Change Detected
- Check39 days agoChange DetectedThe page’s site revision indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check46 days agoChange DetectedRevision from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check75 days agoChange Detected- Revision: v3.5.0 implemented. - Previous revision: v3.4.3 removed. - No visible changes to study details or page content.SummaryDifference0.1%

- Check82 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3. No substantive content changes observed.SummaryDifference0.1%

- Check111 days agoChange DetectedRevision: v3.4.2 is now displayed on the page, replacing the previous Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.